Recent Blog Articles
Post-pandemic weight loss: There’s an app for that
Cognitive behavioral therapy for insomnia by telemedicine: Is it as good as in-person treatment?
Prediabetes diagnosis as an older adult: What does it really mean?
Is blood sugar monitoring without diabetes worthwhile?
Large review study finds low risk of erectile dysfunction after prostate biopsy
Does exercise help protect against severe COVID-19?
A new Alzheimer’s drug has been approved. But should you take it?
Need physical therapy? 3 key questions your PT will ask
COVID-19 vaccines: Safe and effective for American Indian and Alaskan Native communities
Should we track all breakthrough cases of COVID-19?
Jorg Dietrich, MD, PhD
Contributor
Jorg Dietrich, MD, PhD, MMSc, FANA, FAAN, is the director of the Cancer & Neurotoxicity Clinic and Brain Repair Research Program at the Massachusetts General Hospital (MGH) Cancer Center, associate professor of neurology at Harvard Medical School, and attending physician at MGH.
His clinical interests are management of patients with benign and malignant brain tumors and neurologic complications of cancer therapy, including toxicity from radiation, chemotherapy, and immunotherapies. His research activities include clinical, translational, and basic research in the fields of brain tumor biology, biomarkers of cancer, neurotoxicity from cancer therapies, and brain repair mechanisms.
Dr. Dietrich is the author of over 150 publications, including original research articles, review papers, book chapters, and other scientific contributions. His work has been supported by the National Institute of Health, the American Cancer Society, the American Academy of Neurology, and other foundations.
